Depression Burden Runs High in Adults With Systemic Lupus in Jazan
Depressive symptoms were strikingly common among adults living with systemic lupus erythematosus in the Jazan region of Saudi Arabia, reaching 80% in this cross-sectional cohort. In a disease already marked by fluctuating inflammation, organ involvement, fatigue, and treatment burden, the psychiatric load was not a marginal finding. It was central to the clinical picture.
Among 112 adults with SLE evaluated in rheumatology clinics and day-care units at referral hospitals in Jazan, most participants were women, reflecting the known female predominance of lupus. Ages ranged from 18 to 59 years. Depression severity was distributed across the spectrum rather than concentrated in one extreme: 25 participants had mild symptoms, 28 had moderate symptoms, 22 had moderate-to-severe symptoms, and 15 had severe symptoms.
The pattern matters because symptom burden in SLE rarely stays in one compartment. Pain, fatigue, sleep disruption, perceived disability, and immune activity can reinforce one another until mood symptoms become part of the disease’s functional footprint. In daily practice, that means depression is not a separate issue to be screened once the rheumatologic work is done. It belongs inside the same visit.
PHQ-9 Screening Captured a Broad Psychiatric Signal
The study used the Patient Health Questionnaire-9 to assess depressive symptoms, a practical tool in busy outpatient settings because it can be deployed without specialized psychiatric infrastructure. Chi-square testing and binary logistic regression were then used to identify associations with depressive symptoms.
The findings fit a long-standing concern in lupus care: psychiatric morbidity is common, but it is often underrecognized when attention is fixed on serology, flares, and organ-specific complications. Depressive symptoms can worsen adherence, reduce activity, intensify fatigue, and distort a patient’s ability to report or interpret changes in disease status. In an autoimmune illness where self-management is already demanding, mood symptoms can become a multiplier of risk.
A wide prevalence gap exists across prior SLE studies, and this Jazan cohort sits toward the higher end of that range. Earlier Saudi studies cited in the paper have reported depressive symptom prevalence as high as 67.6%, with other regional estimates near 46% and lower rates in some cohorts. The variation is not surprising. Different instruments, case definitions, disease mixes, and healthcare settings will all shift the observed rate. What does remain consistent is the direction of the problem: lupus and depression travel together far too often.
Physical Activity Emerged as the Main Modifiable Association
In multivariable analysis, physical activity stood out as the only clearly modifiable factor linked to depressive symptoms. Physical activity as a categorical variable did not meet overall statistical significance, with a global p value of 0.067, yet one comparison was still clinically meaningful: participants performing less than 150 minutes of physical activity per week were significantly less likely to experience depressive symptoms than those reporting no physical activity at all, with an OR of 0.28 and a 95% CI of 0.10–0.82.
The direction of that association deserves careful reading. It suggests that complete inactivity may carry the greatest psychiatric burden, while even limited movement could be better than none. That pattern is biologically plausible. Physical activity can influence inflammatory tone, sleep quality, energy regulation, and perceived control over chronic illness, all of which matter in lupus. In a disease where fatigue often discourages movement, the relationship can become circular: depression reduces activity, inactivity worsens mood, and both can erode function.
One sentence from the data stands out with unusual force: no physical activity was the worst reference point. In practical terms, the absence of movement may be a marker for broader symptom burden, restricted mobility, pain, fear of flares, or low mood itself. The study cannot separate all of those pathways, but it does show that inactivity deserves attention as more than a lifestyle footnote.
Screening Has to Happen Where Lupus Is Treated
The cohort was drawn from adults attending referral hospitals in Jazan between September and December 2023, using convenience sampling because no complete regional registry was available. SLE diagnosis was established by treating rheumatologists and medical records under the 2019 EULAR/ACR classification criteria. The study was observational and cross-sectional, so it cannot prove causation or show whether depression preceded lupus severity, followed it, or moved alongside it.
Even so, the clinical takeaway is direct. Routine depression screening should be built into lupus care, especially in regions where psychiatric resources may be uneven and where the burden of chronic disease intersects with limited specialist access. Screening is only the first step, but it is the one that identifies who needs assessment, counseling, behavioral support, medication review, or referral.
The authors also framed the findings in the context of Saudi data showing that psychiatric disorders and depressive symptoms are already common in SLE populations across multiple regions. Jazan has now joined that picture with local evidence rather than inference. For clinicians, that matters because local prevalence estimates are often more persuasive than imported assumptions when service planning is decided.
A Cross-Sectional Snapshot With Real-World Limits
Several limitations are built into the design. The sample was relatively small at 112 patients, drawn by convenience rather than random sampling, and the study was limited to one region and two referral hospitals. Depression was assessed with a screening instrument rather than a formal psychiatric interview, so the data describe depressive symptoms, not necessarily diagnosed major depressive disorder.
The study’s privacy restrictions also prevent public sharing of the underlying data, which limits external verification. Still, the results are clinically coherent and operationally useful. In lupus clinics, mood screening should not wait for crisis-level dysfunction, and inactivity should not be dismissed as an inevitable byproduct of chronic autoimmune disease. It may be one of the most visible places where psychiatric and rheumatologic care intersect.
The study leaves one practical question open: whether structured physical activity support can reduce depressive symptoms in this population while remaining safe and realistic for patients with active or fluctuating lupus. That question now belongs to interventional work, not more cross-sectional counting.